Loading...

Follow ACG BLOG - IBD on Feedspot

Continue with Google
Continue with Facebook
or

Valid
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Editor David T. Rubin, MD, FACG, and an Associate Editor select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Stephen B. Hanauer, MD, FACG
Dr. Hanauer
2018 J. Edward Berk Distinguished Lecture: Fake News and Alternative Facts on Personalized Medicine in IBD

At the ACG 2018 Annual Scientific Meeting, Dr. Hanauer presented a Special Lecture in which he discussed best practices in IBD and differentiated the supporting evidence from the current misinformation and misunderstandings that detract from optimal patient care.

Watch and listen HERE

No CME is available for this video.

The post Video of the Week: Dr. Stephen B. Hanauer: Fake News and Alternative Facts on Personalized Medicine in IBD appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

{This monograph is a product of the ACG Innovation & Technology (ad-hoc) Committee}
Authors & Committee Members: Sarah Enslin, PA-C, Seth A Gross, MD, FACG; Aasma Shaukat, MD, MPH; Daniel Castaneda, MD, Drew Schembre, MD, Laith Jamil, MD, Marta L. Davila, MD, FACG; Prasad G. Iyer, MD, MS, FACG; Christopher Y. Kim, MD, FACG; Vladimir M. Kushnir, MD, Amandeep K. Shergill, MD, MS; Mark B. Pochapin, MD, FACG; David T. Rubin, MD, FACG; Jay N. Yepuri, MD, MS, FACG and Vivek Kaul, MD, FACG (Committee Chair)

In the last decade, gastroenterology practice has experienced exponential growth in innovation and new technology, both in the pharmaceutical and device sectors. New products have impacted the practice of gastroenterology, endoscopy and hepatology. Patients are aware and well informed on these innovations and specifically request them.

In this evolving landscape, and to keep our members abreast of the evolving technology and innovations, ACG leadership felt strongly that the College should develop a forum which allows members to gather the information related to these new ideas, innovations and technologies.

This impetus led to the creation of the new ACG Innovation & Technology Committee which has a multi-faceted mission. A few examples of the committee’s charge include generation of technology assessment reports, reviews and white papers related to new technology and innovation in Gastroenterology, collaboration with the ACG hands-on endoscopy workshops for training and education in new technology and liaising with our industry partners to address current gaps in the device/innovation realm.

The Most Innovative and Impactful Abstracts at ACG 2018

As one of its first tasks, the Committee summarized the most recent technology-related papers presented at the ACG 2018 Annual Scientific Meeting to highlight their clinical significance. The papers selected by the new ACG Innovation & Technology Committee are summarized below.

Complete Abstracts and References can be accessed here

A. Innovations in Pharmacotherapeutics

Inflammatory Bowel Disease

1. Sandborn et al. presented a phase 2 induction study of etrasimod (APD334), a selective, oral sphingosine 1-phosphate (S1P) receptor modulator. 156 patients with moderate to severe ulcerative colitis were randomized to once daily (1) etrasimod 1mg, (2) etrasimod 2mg, or (3) placebo. Etrasimod was more effective than placebo, at the 2mg dose (p=0.009).

2. Sands et al. presented a phase 3 UNIFI study on the safety and efficacy of ustekinumab (UST) induction therapy in patients with moderate to severe ulcerative colitis. 961 patients who failed conventional treatment or biologic therapies were randomized into 3 cohorts: (1) 130mg IV induction dose of UST, (2) weight-based dose of UST 6mg/kg, or (3) placebo. Patients who received UST in either dose combination had a higher likelihood of achieving clinical remission, endoscopic healing, clinical response, and mucosal healing at week 8 compared to those who received placebo (p<0.001).

Irritable Bowel Syndrome

3. Lembo et al. studied tenapanor, a selective small molecule inhibitor of the intestinal sodium-hydrogen exchanger-3 (NHE3), for IBS-C. In this safety study, 240 patients were observed for up to 52 consecutive weeks on tenapanor 50mg BID. This medication was well tolerated, with only 2.1% discontinuing it due to adverse events. Most common AE was diarrhea (9.2%), resulting in 1.6% discontinuation rate.

4. Brenner et al. presented a randomized, double-blind study comparing eluxadoline 100 mg twice daily (mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist)  to placebo in patients with IBS-D. 346 patients were enrolled with a primary endpoint improving worst abdominal pain (WAP) ≥ 40% and Bristol stool score (BSS) < 5 or absence of bowel movement accompanied by ≥ 40% WAP.  More patients who received eluxadoline vs placebo reached the primary endpoint (22.7% vs 10.3%, p=0.0022). The eluxadoline arm had improved stool consistency and WAP compared to placebo (27.9% vs 16.7%, p=0.0119; 43.6% vs 31.0%, p=0.0174).

5. Rao et al. studied an orally-administrated Vibrant capsule improving constipation by inducing vibrations in the colon. 182 patients received a single vibration session and 63 patients received three vibration sessions/day. The arm with multiple vibration sessions had a higher rate of complete spontaneous bowel movements (CSBMs) (p<0.0357), hence improving constipation.

Microbiota Therapy

6. Khanna et al. studied an oral microbiota-restoration therapy (RBX7455) to prevent recurrent Clostridium difficile infection (rCDI). Thirty patients who have had ≥ 2 CDI episodes were enrolled to receive either (1) 4 capsules twice daily for 4 days, (2) 4 capsules twice daily for 2 days, or (3) 2 capsules twice daily for 2 days. At 8 weeks, 90% of patients remained negative for rCDI (90% in cohort 1, 80% in cohort 2, and 100% in cohort 3).

Liver

7. Basu et al. studied the efficacy of Sofosbuvir, Velpatasvir, and Veloxpravir in the treatment of patients triple infected with HBV, HIV, and HCV genotype 3 (treatment naïve). 22 patients were recruited. SVR was achieved in 87% of this cohort, demonstrating efficacy of DAAs in a very challenging population.

B. Innovations in Endoscopy

Colonoscopy Bowel Preparation

8. Bachwich et al. presented a Phase 2 study evaluating DCL-101, a novel pill for colon prep, compared to standard 4L polyethylene glycol-electrolyte lavage solutions (PEG-ELS).  DCL-101 was better tolerated, with patient ratings of superior taste and tolerability relative to PEG-ELS. Boston Bowel Preparation Score were equivalent in both groups. This could lead to improved patient compliancy when preparing for colonoscopy.
9. Strauss et al. presented a poster on their development of a multidisciplinary clinical care pathway to improve inpatient colonoscopy bowel preparations (BP). An inpatient protocol was developed utilizing note templates and order sets, and key stake holders were trained. In 121 patients pre-intervention and 129 patients post-intervention, they observed an increase in adequate BP in the post-intervention cohort (60.8 vs 79.3%, 95% CI 30.1 to 30.7, p=0.0424).

Improving Adenoma Detection

10. Anderson et al. compared total underwater colonoscopy (TUC) versus CO2 colonoscopy for adenoma detection. 121 participants underwent tandem colonoscopies, 61 having CO2 first followed by TUC and 60 underwent TUC first followed by CO2. Overall polyp miss rate was significantly higher for the TUC first group (34%) versus the CO2 first group (22%), p=0.002. Based on this study, TUC was suboptimal to CO2 in colon insufflation and polyp detection.

11. Rex et al. reported Endocuff decreased examination time (p<0.0001) with no loss of detection of polyps compared to standard colonoscopy (SC) in 200 patients.  Endocuff also demonstrated higher adenomas per colonoscopy, adenoma detection rate, sessile serrated polyps (SSP) per colonoscopy, and SSP detection rate vs SC.

Endoscopy

12. Abdul Hamid El-Chafic et al. studied liver biopsy specimen quality, complication rates, and recovery times in patients who underwent a liver biopsy via different techniques; EUS guided liver biopsy (EUS-LB) using 19-gauge core biopsy needle via modified one pass, one actuation wet suction technique, percutaneous liver biopsy (PC-LB) using a 16-gauge core biopsy needle, and transjugular liver biopsy (TJ-LB) via 19-gauge biopsy needle were evaluated. Fewer needle passes were performed in EUS-LB and PC-LB groups, compared to TJ-LB, p<0.001. EUS-LB produced significantly more complete portal triads compared to PC-LB (p<0.001). EUS-LB produced significantly longer aggregate length compared to PC-LB and TJ-LB (p<0.05). Post-procedure recovery time was less among patients undergoing EUS-LB (p<0.05). The rates of complications among all 3 groups were similar.

13. Kantsevoy et al. studied a new endoluminal interventional platform (Lumendi LLC, USA) to improve stabilization for colonic lesions. 137 lesions were removed (126 Endoscopic submucosal dissection (ESD), 11 endoscopic mucosal resection (EMR)). En bloc resection rate in the EMR group was only 18.2%, however en bloc resection rate in the ESD group was 87.1%. Mean endoscopic intervention time was 45.0 ± 40.6 minutes. No significant adverse events occurred, demonstrating a safe and effective platform.

14. Wang et al. presented a poster addressing gastric variceal bleeding and treatment options. EUS-guided coil embolization and absorbable gelatin sponge (Gelfoam) was compared to cyanoacrylate injection (CYA) alone. Five patients treated with Gelfoam were matched in a 1:4 fashion to 20 patients who received CYA. The Gelfoam arm did not require re-intervention at 3 months, compared to 56% of patients who received CYA who did (p=0.046). 3 month mortality in Gelfoam arm was 0% vs 20% in CYA group, p=0.55. Post-procedural hospitalization (3.4 ± 2.2 days vs 8.6 ± 9.9 days, p=0.26) and lower post-procedure transfusion requirements (0.2 ± 0.4 units of blood vs 1.95 ± 2.70 units of blood, p=0.17), favored the Gelfoam arm.  Further long-term studies are needed to validate these findings.

Pancreas

15. Hrad et al. studied EUS-guided microforceps to improve pancreatic cystic neoplasms (PCN) diagnosis. Thirty-seven patients (38 cysts) were sampled with EUS-guided microforceps. Cell block samples were analyzed, providing definitive diagnosis in 35/38 cysts (92%). The series demonstrates EUS-microforceps cyst wall biopsy may help better diagnose pancreas cyst type.

16. Zhong et al. studied the role of contrast-enhanced EUS (CE-EUS) to diagnose PCN. 82 patients with suspected PCNs underwent CE-EUS. All patients subsequently underwent surgical resection and pathology confirmation was obtained. The diagnostic accuracy of CE-EUS was greater than CT or MRI (CE-EUS vs CT: 92.3% vs 76.9%, p<0.05; CE-EUS vs MRI: 93.0% vs 78.9%, p<0.05).

17. Linghu et al. studied endoscopic ultrasonography-guided radiofrequency ablation (EUS-RFA) combined with lauromacrogol ablation (LA) for PCNs. Twenty-one patients were included, 5 with MCNs and 16 with serous cystadenomas. Imaging 3 months post-treatment in 17 patients demonstrated complete response in 8 patients (47%), partial response in 6 patients (35%), and persistent cysts in 3 patients (18%). One patient developed mild acute pancreatitis, 1 patient had hyperamylasemia, and 2 patients developed abdominal pain post-procedure. This was a short-term study and the long-term efficacy is yet to be determined.

Artificial Intelligence (AI)

18. Requa et al. used a convolutional neural network (CNN) to predict colon polyp size and width. The CNN predicted size accuracy of 0.97 for polyps < 6mm, 0.97 for polyps 6-9mm, and 0.98 for polyps > 9mm, demonstrating a role for AI to evaluate colon polyps.

19. Guo et al. studied automatic detection of esophageal precancerous and early squamous cancer lesions using AI software. The sensitivity for precancerous lesions or early esophageal squamous cancer was 97.1% and sensitivity for all malignant images was 97.8%. There was however a high false positive rate with specificity of all non-cancerous images of only 76.2%.

C. New Techniques & Care Pathways

Flexible Robotic Endoscopy

20. Gross et al. demonstrated a robotic assisted endoscopic submucosal dissection.  Allowing the endoscopists to have a stable platform and tissues traction, Flexible Robotic Endoscopy is a novel, operator-controlled, computer-assisted endoscope platform to assist with EMR/ESD. This endoscope has two accessory channels and a 3D-HD digital camera. The device was tested by an endoscopist with no prior ESD (or robotic) experience, and assessed the operator’s ability to perform distal colonic ESD in a cadaver with suture closure of the defect. A human case demonstrating a recto-sigmoid polyp ESD removal was also shown. This is the first reported experience of this platform with further clinical assessment to come.

Healthcare Delivery Enhancement

21. Tran et al. demonstrated the use of a multidisciplinary team (Enteral Access Team [EAT]) to reduce unnecessary G-tube placement for end of life patients. 49 patients were evaluated by the EAT, 32 (65%) underwent G-tube placement. 94% of the patients who did not have a G-tube placed were end of life. These patients had a decrease in expected length of stay, lower readmission rates, and increased rate of discharge to home.

22. Roth et al. studied the role of telemedicine in an IBD population. The patients who used telemedicine experienced fewer hospitalizations with an increase in non-invasive testing. 29 participants from the TELE-IBD study agreed to participate in a qualitative assessment which was presented at this meeting. 15 of the 29 participants adhered to the self-monitoring program during the course of the trial. These interviews revealed patients felt TELE-IBD was most helpful for those having an IBD flare and for those with shorter duration of disease.

Summary

As highlighted above, the portfolio of innovation and technology related presentations at the 2018 ACG Annual Meeting spans the entire gamut of Gastroenterology. As the evidence base and experience builds up, many of these technologies and innovations will no doubt begin to find a place in modern GI practice sooner or later and impact patient care in a significant manner.

The post Innovation & Technology in Gastroenterology and Hepatology Highlights from the 2018 ACG Annual Scientific Meeting appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Editor David T. Rubin, MD, FACG, and an Associate Editor select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Francis A. Farraye, MD, MSc, FACG,
Boston Medical Center, Boston University School of Medicine IBD: The First Visit

Francis A. Farraye, MD, MSc, FACG

In this presentation from the 2017 What’s New in GI Pharmacology Course, Dr. Farraye reviews appropriate tests, vaccinations, referrals and medications needed for patients with IBD on their first visit, depending on disease activity.

Watch and listen HERE.

No CME is available for this video.

The post Video of the Week: Dr. Francis Farraye on IBD: The First Visit appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

J. EDWARD BERK DISTINGUISHED LECTURE
Stephen B. Hanauer, MD, FACG
Fake News and Alternative Facts on Personalized Medicine in IBD

Tuesday, October 9 | 10:05 am – 10:35 am | Terrace Ballroom 2-3

Stephen B. Hanauer, MD, FACG

Hear about best practices in IBD and learn how to differentiate the supporting evidence from the current misinformation and misunderstandings that detract from optimal patient care when Dr. Stephen Hanauer presents ACG’s J. Edward Berk Distinguished Lecture.

Stephen B. Hanauer is past President of the ACG (2014-2015). He completed a medical degree, with honors, at the University of Illinois in Chicago. His postdoctoral training included an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at the University of Chicago. He served as the Joseph B. Kirsner Chair Professor of Medicine and was Chief of the Section of Gastroenterology, Hepatology and Nutrition where he served from 2000-2014. Dr. Hanauer is currently the Medical Director of the Digestive Health Center at Northwestern Feinberg School of Medicine and Clifford Joseph Barborka Professor of Medicine. Dr. Hanauer has authored over 400 peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. He is ex-Editor-in-Chief of Nature Clinical Practice Gastroenterology & Hepatology and served as Associate Editor (IBD) of Clinical Gastroenterology and Hepatology. He is a member of the editorial boards of numerous journals, including The American Journal of Gastroenterology and Inflammatory Bowel Diseases.

About the J. Edward Berk Distinguished Lecture: The J. Edward Berk Distinguished Lecture is awarded to individuals prominent in gastroenterology or a related area. The lecturer is nominated by the ACG President and the appointment is subject to approval by the ACG Board of Trustees. The lectureship was established in recognition of the significant contributions made by J. Edward Berk, MD, MACG, to clinical gastroenterology during his long and distinguished clinical and academic career. A nationally and internationally renowned physician and teacher, Dr. Berk also served as ACG President from 1975-1976.

The post J. Edward Berk Distinguished Lecture: Fake News and Alternative Facts on Personalized Medicine in IBD appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

*EMBARGOED All research presented at the 2018 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Monday, October 8, 2018, at 8:00 am EDT.

Mohammed Z. Sheriff, MD

P1382 The Prevalence of Opportunistic Infections in Crohn’s Disease and Ulcerative Colitis Varies by Gender

Author Insight from Mohammed Z. Sheriff, MD, University Hospitals Cleveland Medical Center

What’s new here and important for clinicians?

It has been proposed that opportunistic infections are more common in inflammatory bowel disease (IBD), however there has been a lack of large population-based studies on the risk of opportunistic infections in IBD. This study is the largest of its kind to identify the risk of opportunistic infections in IBD. It emphasizes to clinicians that while these diseases are rare, they are an important consideration for patients with IBD.

What do patients need to know?

A diagnosis of IBD puts patients at increased risk of infection and may even suggest a need for screening or vaccinations.

Read the Abstract

Figure 1

Author Contact
Mohammed Z. Sheriff, MD, University Hospitals Cleveland Medical Center
Mohammed.Sheriff@UHhospitals.org

Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at bdavis@gi.org or by phone at 301-263-9000.

The post P1382 The Prevalence of Opportunistic Infections in Crohn’s Disease and Ulcerative Colitis Varies by Gender appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Co-Editors Philip O. Katz, MD, FACG, and David T. Rubin, MD, FACG, select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Ralf Kiesslich, MD, PhD, K & L Kongress Enhanced Imaging for Detection of Dysplasia in IBD Surveillance

Ralf Kiesslich, MD, PhD

In this presentation from the 2017 ACG Postgraduate Course, Prof. Dr. Kiesslich reviews the optimal approach to detection and management of dysplasia in IBD surveillance.

Watch and listen HERE.

No CME is available for this video.

The post Video of the Week: Ralf Kiesslich, MD, PhD, on Enhanced Imaging for Detection of Dysplasia in IBD Surveillance appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Co-Editors Philip O. Katz, MD, FACG, and David T. Rubin, MD, FACG, select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Gerhard Rogler, MD, PhD, University Hospital Zürich Use of Anti-TNF Antibodies, Drug Levels, and Other Serological Markers in IBD

Gerhard Rogler, MD, PhD

In this presentation from the 2017 ACG Postgraduate Course, Professor Rogler enumerates the indications and clinical applications of anti-TNF antibodies and other prognostic serological markers for IBD management.

Want to earn CME?

Follow these easy steps to log in to your account and access the video:

-Visit gi.org
-Log in using your Single Sign-on Account
-Then click Here
-The video “Use of Anti-TNF Antibodies, Drug Levels, and Other Serological Markers in IBD” will appear at the top of the list.
-Click “Add to Portfolio” then “CONTINUE
-Click “View It” then “View Presentation

Don’t need CME? Watch and listen HERE.

The post Video of the Week: Gerhard Rogler, MD, PhD, on Use of Anti-TNF Antibodies, Drug Levels, and Other Serological Markers in IBD appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Co-Editors Philip O. Katz, MD, FACG, and David T. Rubin, MD, FACG, select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Charles N. Bernstein, MD, FACG, University of Manitoba Diet, FMT, and Other Non-pharmacological Management
Options for IBD

Charles N. Bernstein, MD, FACG

In this presentation from the 2017 ACG Postgraduate Course, Dr. Bernstein discusses the role of diet, use of FMT, and other non-pharmacological therapies in the management of IBD.

Want to earn CME?

Follow these easy steps to log in to your account and access the video:

-Visit gi.org
-Log in using your Single Sign-on Account
-Then click Here
-The video “Diet, FMT, and Other Non-pharmacological Management Options for IBD” will appear at the top of the list.
-Click “Add to Portfolio” then “CONTINUE
-Click “View It” then “View Presentation

Don’t need CME? Watch and listen HERE.

 

The post Video of the Week: Charles N. Bernstein, MD, FACG, on Diet, FMT, and Other Non-pharmacological Management Options for IBD appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

David T. Rubin, MD, FACG

Sherman Prize Accepting Nominations of Outstanding IBD Professionals Deadline: April 15, 2018

David T. Rubin, MD, FACG, Chair, Sherman Prize Selection Committee

Excellence. Inspiration. Hope. Pioneers. These words have become synonymous with the Sherman Prize, which rewards health care providers, medical researchers, public health advocates and educators who have made exceptional contributions in the fight to overcome Crohn’s disease and ulcerative colitis.

Nominations are now being accepted online at ShermanPrize.org for the third annual Sherman Prize cycle. I’m honored to Chair this year’s selection committee and would love to see my fellow ACG members represented in the nominations.

If you know someone who never gives up fighting for their IBD patients, who goes above and beyond to make life better for people with Crohn’s and ulcerative colitis, who never stops innovating, then now is the time to honor their achievements by nominating them for one of this year’s Sherman Prizes.

Two Sherman Prizes of $100,000 each will be awarded to individuals with extraordinary track records of achievement addressing the challenges of IBD, and a $25,000 Sherman Emerging Leader Prize will be awarded to an individual who demonstrates high potential. All prize recipients will also be featured in short videos that highlight their groundbreaking work. These stories of achievement are featured prominently on the new Sherman Prize website, in support of the mission to create a ripple effect of inspiration in the IBD community.

Here are a few more specifics about the prize:

  • The Sherman Prize will accept nominations through April 15, 2018 for individuals who have made significant, noteworthy contributions in patient care, medical research, public service and education.
  • Eligible individuals must live and work in the U.S., having accomplished their greatest achievements in the past decade. Greater emphasis will be placed on accomplishments made in the last few years.

To learn more about the Sherman Prize and previous recipients, and to nominate an exceptional individual, please visit ShermanPrize.org.

Submit a nomination and to learn more about the prize and last year’s recipients.

The Shermans and 2017 Sherman Prize Winners

The post Sherman Prize Accepting Nominations of Outstanding IBD Professionals appeared first on American College of Gastroenterology.

  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Explore the ACG Education Universe with Weekly Picks by Co-Editors

The ACG Education Universe is a robust online educational library featuring video presentations from ACG’s national and regional meetings.

To help guide you through the wealth of content available FREE to ACG members, each week Co-Editors Philip O. Katz, MD, FACG, and David T. Rubin, MD, FACG, select a video to highlight. The focus is on clinically relevant topics that delve into issues you see commonly as well as practice management insights to enhance your success.

To earn CME for watching this video, below are detailed instructions on how to access credit, but if you prefer just to review the video without earning CME, an open-access link is provided.

THIS WEEK: Corey A. Siegel, MD, MS, Geisel School of Medicine at Dartmouth, Darthmouth-Hitchcock Medical Center Refocusing IBD Patient Management: Personalized, Proactive,
and Patient-Centered Care

Corey A. Siegel, MD, MS

In this presentation from the World Congress of Gastroenterology at ACG2017 Scientific Meeting, Dr. Siegel describes how IBD patient care can be improved by optimizing and individualizing the treatments currently available.

Watch and listen HERE.

No CME is available for this video.

The post Video of the Week: Corey A. Siegel, MD, MS, Gives the AJG Lecture–Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care appeared first on American College of Gastroenterology.

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview